Evidence map›Paper›PMID 34661974›Full record

ArticleMolecular systems biology2021

Cell-to-cell and type-to-type heterogeneity of signaling networks: insights from the crowd.

Attila Gabor, Marco Tognetti, Alice Driessen, Jovan Tanevski, Baosen Guo, Wencai Cao, He Shen, Thomas Yu, Verena Chung, Single Cell Signaling in Breast Cancer DREAM Consortium members and 2 more

Abstract read
In one paragraph

Article in Molecular systems biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Attila GaborInstitute for Computational Biomedicine, Heidelberg University and Heidelberg University Hospital, Faculty of Medicine, Bioquant, Heidelberg, Germany.ORCID 0000-0002-0776-1182
Marco TognettiDepartment of Quantitative Biomedicine & Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-2379-1525
Alice DriessenInstitute for Computational Biomedicine, Heidelberg University and Heidelberg University Hospital, Faculty of Medicine, Bioquant, Heidelberg, Germany.ORCID 0000-0002-8822-2606
Jovan TanevskiInstitute for Computational Biomedicine, Heidelberg University and Heidelberg University Hospital, Faculty of Medicine, Bioquant, Heidelberg, Germany.
Baosen GuoDivision of AI & Bioinformatics, Shenzhen Digital Life Institute, Shenzhen, China.ORCID 0000-0001-7554-8677
Wencai CaoDivision of AI & Bioinformatics, Shenzhen Digital Life Institute, Shenzhen, China.
He ShenDivision of AI & Bioinformatics, Shenzhen Digital Life Institute, Shenzhen, China.
Thomas YuSage Bionetworks, Seattle, WA, USA.
Verena ChungSage Bionetworks, Seattle, WA, USA.
Single Cell Signaling in Breast Cancer DREAM Consortium members
Bernd BodenmillerDepartment of Quantitative Biomedicine & Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-6325-7861
Julio Saez-RodriguezInstitute for Computational Biomedicine, Heidelberg University and Heidelberg University Hospital, Faculty of Medicine, Bioquant, Heidelberg, Germany.ORCID 0000-0002-8552-8976

Funding

Single-Cell Analyses of Human Islets in T1D Using Highly Multiplexed ImagingUC4DK108132 · NIDDK · UNIVERSITY OF FLORIDA · PI ATKINSON, MARK A., BODENMILLER, BERND · 2015 to 2015
$3.6M
Cancer Research UKNIDDK NIH HHS UC4 DK108132
6 · The paper itself

Abstract

Recent technological developments allow us to measure the status of dozens of proteins in individual cells. This opens the way to understand the heterogeneity of complex multi-signaling networks across cells and cell types, with important implications to understand and treat diseases such as cancer. These technologies are, however, limited to proteins for which antibodies are available and are fairly costly, making predictions of new markers and of existing markers under new conditions a valuable alternative. To assess our capacity to make such predictions and boost further methodological development, we organized the Single Cell Signaling in Breast Cancer DREAM challenge. We used a mass cytometry dataset, covering 36 markers in over 4,000 conditions totaling 80 million single cells across 67 breast cancer cell lines. Through four increasingly difficult subchallenges, the participants predicted missing markers, new conditions, and the time-course response of single cells to stimuli in the presence and absence of kinase inhibitors. The challenge results show that despite the stochastic nature of signal transduction in single cells, the signaling events are tightly controlled and machine learning methods can accurately predict new experimental data.

Indexed as

Breast NeoplasmsSignal TransductionFemaleHumansMachine LearningProteinsProteinscell signalingcrowdsourcingmass cytometrypredictive modelingsingle cell

Identifiers

PMID34661974
PMCPMC8522707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.